GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

latozinemab   Click here for help

GtoPdb Ligand ID: 13685

Synonyms: AL-001 | AL001
Compound class: Antibody
Comment: Latozinemab (AL001) is an anti-sortilin 1 (SORT1) monoclonal antibody. It is proposed to elevate progranulin levels by inhibiting the SORT1-mediated degradation pathway for progranulin (PGRN). This mechanism is being investigated as a disease‐modifying therapy for patients with frontotemporal dementia caused by loss-of-function mutations in GRN.
No information available.
Summary of Clinical Use Click here for help
Latozinemab (AL001) is being investigated in clinical trials to determine safety and efficacy for the treatment of neurodegenerative diseases and wet age-related macular degeneration (wAMD). In February 2024, the FDA granted latozinemab breakthrough therapy designation as a treatment for frontotemporal degeneration (frontotemporal dementia).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03987295 A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) Phase 2 Interventional Alector Inc.
NCT06111014 Continuation Study for Latozinemab Phase 3 Interventional Alector Inc.
NCT04374136 A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) Phase 3 Interventional Alector Inc. The INFRONT-3 study
NCT03636204 A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation Phase 1 Interventional Alector Inc. 1